Idera Pharmaceuticals, Inc. IDRA
0.43 +0.43
Day range unavailable
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 1
- 2 months ago 1
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -0.15 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.11 | 0.0% | 0 | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 19, 2021 | Wedbush | Downgrade | Outperform | Neutral |
| Mar 19, 2021 | Barclays | Downgrade | Overweight | Equal-Weight |
| Mar 19, 2021 | JMP Securities | Downgrade | Outperform | Market Perform |
| Mar 19, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 19, 2021 | JP Morgan | Downgrade | Overweight | Neutral |
| Nov 25, 2020 | Barclays | Initiated | — | Overweight |
| Nov 25, 2020 | Wedbush | Maintained | Outperform | Outperform |
| Nov 25, 2020 | Baird | Maintained | Outperform | Outperform |
| Nov 25, 2020 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Nov 25, 2020 | H.C. Wainwright | Initiated | — | Buy |
| Nov 25, 2020 | Baird | Initiated | — | Outperform |
| Nov 25, 2020 | JMP Securities | Initiated | — | Market Outperform |
| Nov 25, 2020 | Wedbush | Initiated | — | Outperform |
| Nov 25, 2020 | JP Morgan | Initiated | — | Overweight |
| Nov 25, 2020 | Cowen & Co. | Initiated | — | Outperform |
| Nov 25, 2020 | PiperJaffray | Initiated | — | Overweight |